Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 4:30 p.m. ET. The presentation will feature CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs and will be webcast on the company’s investor relations website for 30 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Q2 earnings report | Positive | +4.9% | Quarterly revenue increased 5%, but product trends and expenses were mixed. |
| Jul 29 | Earnings date notice | Neutral | +2.1% | Company scheduled second-quarter results and its related conference call. |
| May 27 | Conference presentation | Neutral | +1.5% | Company announced participation in the Jefferies Healthcare Conference. |
| May 07 | Q1 earnings report | Negative | -20.9% | Gross margin declined alongside substantially lower quarterly net income. |
| May 06 | Conference presentation | Neutral | +2.2% | Company announced participation in the Bank of America Health Care Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AMPH's prior news reactions were positive in four of five events, while the May 7 earnings release produced a negative reaction.
Key Terms
active pharmaceutical ingredients technical
intranasal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, and our other filings or reports that we may file with the SEC. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-21st-annual-healthcare-conference-302865707.html
SOURCE Amphastar Pharmaceuticals, Inc.